Norn Notes 20251201
Nucleus Genomics is a longevity company?
We’re starting a new type of post, Norn Notes. Between longer essays, we’ll post quick takes on longevity news worth watching.
Nuclear Marketing
Nucleus Genomic launched a massive consumer marketing campaign, which triggered/resurfaced multiple critiques of their science and integrity [1, 2, 3]. The CEO attempted a rebuttal, not very successfully.
Two points are relevant for the longevity field:
The stakes for the discussion are high because the commercial success drivers for polygenic risk embryo cos are brand and sales, with science as a nice-to-have support. This is because most outcomes of what they are selling are not immediately verifiable. “Decreased risk of Alzheimer’s” won’t be relevant for decades, and you’d need to wait years after a kid is born to even run an IQ test. And in both cases, there’s no control group/counterfactual. So even if the products did literally nothing, the companies wouldn’t get market feedback for a long time (but of course would be letting their customers and humanity down).
The CEO is actively pitching the product as longevity.
These two points are related:
The need to predict future death and disease is the biggest challenge for longevity (i.e., the field of actually giving people more healthy years of life). If we had a validated measurement that tells you how many healthy years you have left, companies would be rewarded for developing treatments that improve the measure. But we only have the embryo of such a test (in the form of various aging clocks and frailty indices), yet to mature into something we can trust. This means uncertainty, which opens the door to emotional and narrative-based marketing.
As the idea of longevity becomes more broadly accepted, people skilled at marketing vibes are seeing a lot of opportunity. Some of this is ‘longevitainment’, selling a desired identity to people with cash to spare. Some is grift, selling unsubstantiated claims as ‘science’. Some might be the nucleus of real consumer longevity products, by gathering the data needed to validate predictors of future health (fear not, we will help you tell the difference).
Biomarkers - 1
Robust ways to measure future health is the most important missing tool for the longevity field. Several relevant papers came out in the last few weeks:
Elastin-derived extracellular matrix fragments drive aging through innate immune activation
TranslAGE: A Comprehensive Platform for Systematic Validation of Epigenetic Aging Biomarkers
A unified framework for systematic curation and evaluation of aging biomarkers
Organ-specific proteomic aging clocks predict disease and longevity across diverse populations
Biomarkers - 2
Martin’s TEDx talk on the need for third-party, standardized benchmarking of potential aging biomarkers went live on Youtube:
This is a preface for a program Norn Group is working on.